CYTH — Cyclo Therapeutics Share News
0.000.00%
Last trade - 00:00- $23.04m
- $34.29m
- $1.08m
Cyclo Therapeutics up as rare disease drug trial enrollment is on track
Brief: Cyclo Therapeutics Provides Clinical Program Update And Highlights Recent Achievements
Brief: Cyclo Therapeutics Announces First Patient Dosed In Phase 2B Study Of Trappsol® Cyclo™ For The Treatment Of Early Alzheimer’S Disease
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Blackstone, Ford
Brief: Cyclo Therapeutics Reports Third Quarter Results
Brief: Cyclo Therapeutics Announces Publication Of Phase 1 Data For Trappsol Cyclo
Brief: Cyclo Therapeutics Commences Phase 2B Study Of Trappsol® Cyclo™ For The Treatment Of Early Alzheimer’S Disease
Brief: Cyclo Therapeutics reports Q2 results
Brief: Cyclo Therapeutics Reports First Quarter 2022 Financial Results
U.S. STOCKS ON THE MOVE-Allego, WeWork, Emclaire
Brief: Cyclo Therapeutics Enters Research And Collaboration Agreement With Wits Commercial Enterprise
Cyclo Therapeutics up on research collaboration for lead drug
Brief: Cyclo Therapeutics Provides Business Update And Reports Full Year 2021 Financial Results
Brief: Cyclo Therapeutics Forms Committee To Advise On Phase 3 Trial For Trappsol Cyclo
NASDAQ RESUMED AT 02:27 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:22 PM
Brief: Cyclo Therapeutics Receives IND Clearance From U.S. FDA To Advance Its Phase 2 Study Of Trappsol® Cyclo™
Cyclo Therapeutics rises on FDA nod for Alzheimer's drug trial
U.S. STOCKS ON THE MOVE-Cyclo Therapeutics, Ballard Power, Roku